Timothy Price, MBBS, DHthSc, FRACP, discusses the safety and efficacy of AMG 510 in patients with advanced gastrointestinal cancers.
Timothy Price, MBBS, DHthSc, FRACP, senior consultant medical oncologist and director of Medical Oncology and Clinical Cancer Research at The Queen Elizabeth Hospital in Adelaide, discusses the safety and efficacy of AMG 510 in patients with advanced gastrointestinal cancers.
The phase 1 results of the CodeBreaK 100 trial were presented during the ESMO Asia Virtual Congress 2020 and focused on the benefit of AMG 510 in patients with colorectal cancer (CRC) and other gastrointestinal cancers. Results showed that the drug was safe, with few toxicities associated with single-agent AMG 510; this was an important finding for a phase 1 study, Price explains. For the patients with colorectal cancer specifically, a signal of activity was observed. The drug elicited a promising response rate and the majority of patients achieved stable disease, adds Price.
Notably, the patients enrolled on the study were heavily pretreated; however, they were able to achieve impressive overall survival and progression-free survival benefit with AMG 510 compared with other standard therapies in the arsenal, Price concludes.